Detailed information for compound 258317

Basic information

Technical information
  • TDR Targets ID: 258317
  • Name: 2-(1-benzoyl-2-ethyl-3-oxamoylindol-4-yl)oxya cetic acid
  • MW: 394.377 | Formula: C21H18N2O6
  • H donors: 2 H acceptors: 5 LogP: 2.7 Rotable bonds: 8
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCc1n(C(=O)c2ccccc2)c2c(c1C(=O)C(=O)N)c(ccc2)OCC(=O)O
  • InChi: 1S/C21H18N2O6/c1-2-13-18(19(26)20(22)27)17-14(9-6-10-15(17)29-11-16(24)25)23(13)21(28)12-7-4-3-5-8-12/h3-10H,2,11H2,1H3,(H2,22,27)(H,24,25)
  • InChiKey: JMDSAENGCRNKCV-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-(1-benzoyl-2-ethyl-3-oxamoyl-indol-4-yl)oxyacetic acid
  • 2-[(1-benzoyl-2-ethyl-3-oxamoyl-4-indolyl)oxy]acetic acid
  • 2-[2-ethyl-3-oxamoyl-1-(phenylcarbonyl)indol-4-yl]oxyethanoic acid
  • 2-[1-(benzoyl)-2-ethyl-3-oxamoylindol-4-yl]oxyacetic acid
  • 2-[1-(benzoyl)-2-ethyl-3-oxamoyl-indol-4-yl]oxyacetic acid
  • 2-[[2-ethyl-3-oxamoyl-1-(oxo-phenylmethyl)-4-indolyl]oxy]acetic acid
  • 2-(2-ethyl-3-oxamoyl-1-phenylcarbonyl-indol-4-yl)oxyethanoic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens phospholipase A2, group IIA (platelets, synovial fluid) Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi Phospholipase A2 family protein phospholipase A2, group IIA (platelets, synovial fluid) 144 aa 125 aa 28.0 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Onchocerca volvulus 0.0177 0 0.5
Trypanosoma cruzi dihydrofolate reductase-thymidylate synthase 0.0573 0.5331 0.5
Trypanosoma brucei dihydrofolate reductase-thymidylate synthase 0.0573 0.5331 0.5
Echinococcus multilocularis dihydrofolate reductase 0.092 1 1
Chlamydia trachomatis dihydrofolate reductase 0.092 1 0.5
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.092 1 1
Schistosoma mansoni dihydrofolate reductase 0.092 1 1
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.0573 0.5331 0.5
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.092 1 1
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.0573 0.5331 0.5
Brugia malayi Dihydrofolate reductase 0.092 1 1
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.092 1 1
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.0573 0.5331 0.5
Loa Loa (eye worm) dihydrofolate reductase 0.092 1 1
Echinococcus granulosus dihydrofolate reductase 0.092 1 1
Leishmania major dihydrofolate reductase-thymidylate synthase 0.0573 0.5331 0.5

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 0.039 uM Inhibition of human nonpancreatic secretory Phospholipase A2 through DOC/PC assay ChEMBL. 8978844
IC50 (binding) = 0.039 uM Inhibition of human nonpancreatic secretory Phospholipase A2 through DOC/PC assay ChEMBL. 8978844
IC50 (binding) = 0.081 uM Inhibition of human nonpancreatic secretory Phospholipase A2 through chromogenic assay ChEMBL. 8978844
IC50 (binding) = 0.081 uM Inhibition of human nonpancreatic secretory Phospholipase A2 through chromogenic assay ChEMBL. 8978844
KB (functional) = 0.34 uM Inhibition of Phospholipase A2 induced contraction of GP lung tissue ChEMBL. 8978844
Mole fraction (functional) = 0.0000098 Mole fraction is the IC50 concentration divided by the total lipid concentration (4000 microM) in DOC/PC assay ChEMBL. 8978844
Mole fraction (functional) = 0.000066 Mole fraction of the IC50 concentration of compound divided by the total lipid concentration (1230 microM) in a chromogenic assay ChEMBL. 8978844

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.